20 articles for GW Carter
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Heteroarylmethoxyphenylalkoxyiminoalkylcarboxylic acids as leukotriene biosynthesis inhibitors.

Abbott Laboratories
Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors.

Abbott Laboratories
Synthesis and 5-lipoxygenase inhibitory activity of 5-hydroperoxy-6,8,11,14-eicosatetraenoic acid analogues.

TBA
Hydroxamic acid inhibitors of 5-lipoxygenase.

TBA
Structural requirements for the inhibition of 5-lipoxygenase by 15-hydroxyeicosa-5,8,11,13-tetraenoic acid analogues.

TBA
O-alkylcarboxylate oxime and
N-hydroxyurea analogs of substituted indole leukotriene biosynthesis inhibitors

TBA
Synthesis of bicyclic thiazolidine PAF antagonists

TBA
Structure-activity relationships of the pyridazinone series of 5-lipoxygenase inhibitors

TBA
1-Phenyl-[2H]-tetrahydropyridazin-3-one, A-53612, a selective orally active 5-lipoxygenase inhibitor

TBA
Structural analysis of 2-aryl-1,3-dione compounds as inhibitors of 5-lipoxygenase

TBA
Rapamycin analogs with reduced systemic exposure.

Abbott Laboratories
Nonsteroidal anti-inflammatory drugs as scaffolds for the design of 5-lipoxygenase inhibitors.

Abbott Laboratories
5-Lipoxygenase inhibitors: synthesis and structure-activity relationships of a series of 1-aryl-2H,4H-tetrahydro-1,2,4-triazin-3-ones.

Abbott Laboratories
In vivo characterization of hydroxamic acid inhibitors of 5-lipoxygenase.

Abbott Laboratories
Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships.

Abbott Laboratories
4-hydroxythiazole inhibitors of 5-lipoxygenase.

Abbott Laboratories
Identification and synthesis of a receptor binding site of human anaphylatoxin C5a.

Abbott Laboratories
Improvements in the minimum binding sequence of C5a: examination of His-67.

Abbott Laboratories
Structure-function studies in a series of carboxyl-terminal octapeptide analogues of anaphylatoxin C5a.

Abbott Laboratories
Synthesis and structure-activity relationships of a series of novel benzopyran-containing platelet activating factor antagonists.

Abbott Laboratories